Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.66 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3637331 | 0.80 | HDAC1 (1.00) | HDAC1HDAC3 | |
| SCHEMBL3142583 | 0.77 | SIGMAR1 (0.79) | HDAC1SIGMAR1ALDH1A1 | |
| SCHEMBL20676124 | 0.75 | SIGMAR1 (0.76) | HDAC1SIGMAR1ALDH1A1 | |
| SCHEMBL22014103 | 0.75 | SIGMAR1 (0.76) | HDAC1SIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2235130 | 0.75 | SIGMAR1 (0.76) | HDAC1SIGMAR1CRBNALDH1A1 | |
| SCHEMBL3094281 | 0.73 | SIGMAR1 (0.67) | HDAC1SIGMAR1ALDH1A1ITGB3ITGA2B | |
| SCHEMBL6023614 | 0.73 | RAB9A (0.55) | HDAC1ALDH1A1LMNA | |
| SCHEMBL5651043 | 0.71 | CXCR4 (0.73) | HDAC1SIGMAR1 | |
| SCHEMBL1160126 | 0.71 | SIGMAR1 (0.62) | HDAC1SIGMAR1LMNAITGB3ITGA2B | |
| Bicarbonate SCHEMBL21981463 | 0.71 | SIGMAR1 (0.85) | HDAC1SIGMAR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389553-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389553-B2 | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324046-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | BRDT, HDAC4, HDAC5 | HDAC1 5/4885BACE1 2064/4885CCNC 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.